Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-383 vs Co-administration of CKD-501, D745, and D150 in Healthy Adults
NCT04810676Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lobeglitazone + empagliflozin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-Time Curve from time zero to the last measurable concentration at 48 hours and Maximum Plasma Concentration at 48 hours. Started Apr 2021; status: completed.
02
Drugs
lobeglitazone + empagliflozin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04810676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04810676.